UCB Shares Jump After Demand for Immunology Drug Bimzelx Boosts Outlook

Shares were up 13%—erasing losses in the year to date—after the company raised its annual guidance for the second time this year, citing strong U.S. demand for its blockbuster drug.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。